Additional sex comb-like 1 (ASXL1) gene encodes the ASXL1 protein, which plays an important role in transcriptional regulation of homeotic gene expression [1] . ASXL1 is frequently mutated in a spectrum of myeloid malignancies, including chronic myelomonocytic leukemia (CMML), myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and acute myeloid leukemia (AML) [2, 3] . Importantly, these mutations are associated with poor prognosis, suggesting an important role of ASXL1 mutations in disease progression [2] [3] [4] . Most of ASXL1 mutations are nonsense/frameshift, resulting in truncated forms of the protein lacking the Cterminal PHD finger [2, 5] , which are detectable in leukemia cell lines [6] . We and others have shown that Asxl1 loss or transgenic expression of a truncated ASXL1 protein in mice (Asxl1
Y588X
Tg) impaired hematopoietic stem/progenitor cell (HSC/HPC) function and led to diverse myeloid malignancies [7] [8] [9] . However, the underlying mechanisms remain largely unknown, hindering the development of targeted therapiecs.
ASXL1 exerts its regulatory effects on chromatin through interaction with other protein complexes such as PRC2 [5] and cohesin [10] . ASXL1 is also required for the activity of BAP1 [11] [12] [13] , a deubiquiting (DUB) enzyme regulating homeobox gene expression by controlling the level of H2AK119Ub in opposition to PRC1-mediated gene repression [11, 12] . Recently, Balasubramani et al. [11] reported that ASXL1 truncation mutations confer an enhanced activity on the ASXL1-BAP1 DUB complex [11] , highlighting the significance of the ASXL1-BAP1 complex in normal biological processes and cancer progression. We hypothesize that the ASXL1 aa1-587 truncation mutant promotes myeloid malignancies by enhancing BAP1 DUB activity.
To test this hypothesis, we first examined whether deleting one Bap1 allele can delay or even eradicate ASXL1 Tg mice revealed a normal architecture (Fig. 1d) . Flow cytometric analyses of the PB, spleen and BM cells showed normalized frequencies of Mac-1
Tg mice compared to that in Asxl1
Tg mice (Fig. 1e, f) . Furthermore, the frequencies of Lin Figure S1E-F) . These data suggest that Bap1 hemizygous deletion in Asxl1 Y588X Tg mice is sufficient to prevent the ASXL1 aa1-587 -driven biased myeloid differentiation and myeloid malignancy.
Truncated ASXL1 has been reported to enhance the catalytic activity of BAP1 [11] . We found that ASXL1 aa1-587 competed with ASXL1 full-length (ASXL1 FL ) to bind to BAP1 as determined by immunoprecipitation (IP) of BAP1 and western blotting using HEK293T cells expressing BAP1 and ASXL1 FL with or without ASXL1 aa1-587 (Fig. 2a) . Interestingly, western blot analyses showed that there was no dramatic differences in global levels of H2AK119Ub and H3K27me3 in their BM cKit Tg mice. Error bars represent mean ± SEM from three mice/genotypes with similar results from two independent experiments. (*p < 0.05, **p < 0.01) + cells amongst four genotypes (Fig. 2b, Supplemental Figure (Fig. 2c) , the expression levels of these genes in Bap1
Δ/+ ;Asxl1
Tg cKit + cells were comparable to WT (Fig. 2c) . Furthermore, chromatin immunoprecipitationqPCR (ChIP-qPCR) using an antibody against H2AK119Ub revealed a significant reduction in H2AK119Ub occupancy at the promoter regions of Hoxa5, Hoxa7, Hoxa9, and Dcbld1 in Asxl1
Tg cKit + cells and in 32D cells expressing ASXL1 aa1-587 (Fig. 2d , supplemental Figure S2B ). Importantly, the H2AK119Ub occupancy was partially restored at the promoter regions of each of these genes tested in Bap1
;Asxl1
Tg cKit + cells (Fig. 2d) . These data indicate that ASXL1 truncation mutations confer gain-of-function in the pathogenesis of myeloid malignancies by increasing BAP1 DUB activity as reducing BAP1 activity ameliorates the abnormal hematopoietic phenotypes in Asxl1
Tg mice. ASXL1 is an obligate regulatory subunit of the BAP1 DUB, and our current findings suggest that a balanced ASXL1-BAP1 axis is critical for normal hematopoiesis. BAP1 is thought to function as a tumor suppressor through its DUB activity. This study uncovers an unexpected oncogenic effect of increased BAP1 activity resulting from truncation of ASXL1 in leukemogenesis. This study discloses, for the first time, that BAP1 may represent a "double-edged sword" in cancer. Future work is warranted to determine whether disruption of the interaction between truncated ASXL1 and BAP1 can circumvent the oncogenic effects of increased BAP1 activity in ASXL1 truncation-driven abnormal hematopoiesis and myeloid malignancy.
